ACADIA Pharmaceuticals (ACAD) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Telix Pharmaceuticals (TLX) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, losing 6.1% versus a loss of 27.4%. ACADIA Pharmaceuticals is the larger company by market cap ($2.96 billion vs $2.84 billion), about 1.0 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +11.9%). On valuation, ACADIA Pharmaceuticals trades at a lower trailing P/E (8.1x vs 83.7x for Telix Pharmaceuticals).
ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | TLX |
|---|---|---|
| Share price | $17.11 | $8.37 |
| Market cap | $2.96B | $2.84B |
| 1-day change | -2.73% | -3.90% |
| YTD return | -35.94% | +11.75% |
| 1-year return | -27.38% | -6.06% |
| 5-year return | -8.94% | — |
| P/E ratio (TTM) | 8.07 | 83.70 |
| Forward P/E | 15.75 | — |
| EPS (TTM) | $2.12 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $803.79M |
| Revenue growth (YoY) | +11.87% | +55.61% |
| Net income (latest FY) | $391.00M | $-7.13M |
| Gross margin | 91.69% | 53.05% |
| Operating margin | 9.78% | 3.70% |
| Net margin | 36.49% | -0.89% |
| 52-week high | $30.96 | $13.11 |
| 52-week low | $15.86 | $6.28 |
| Distance from 52-week high | -44.74% | -36.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +77.21% | +134.89% |
| Average volume | 2.18M | 356.74K |
| Shares outstanding | 172.83M | 339.78M |
| Employees | 796 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLX has outperformed ACAD by 21.3 percentage points over the past year.
- Telix Pharmaceuticals trades at a higher earnings multiple (83.7x vs 8.1x trailing P/E).
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -0.9 cents for Telix Pharmaceuticals.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +11.87%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
ACAD vs TLX FAQ
Which is bigger, ACADIA Pharmaceuticals or Telix Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $2.96B compared with $2.84B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, ACAD or TLX?
TLX returned -6.06% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ACAD or TLX?
ACAD has the lower trailing P/E at 8.1, versus 83.7 for TLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ACADIA Pharmaceuticals and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.